Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma-Reference-Cited by-同舟云学术

Antiapoptotic BCL-2 proteins determine sorafenib/regorafenib resistance and BH3-mimetic efficacy in hepatocellular carcinoma

Published:2018-03-30 Issue:24 Volume:9 Page:16701-16717
ISSN:1949-2553
Container-title:Oncotarget
language:en
Short-container-title:Oncotarget

Author:

Tutusaus Anna¹²,Stefanovic Milica¹,Boix Loreto³,Cucarull Blanca¹²,Zamora Aynara¹,Blasco Laura¹,de Frutos Pablo García¹,Reig Maria³,Fernandez-Checa Jose C.¹⁴⁵,Marí Montserrat¹,Colell Anna¹,Bruix Jordi³,Morales Albert¹³

Affiliation:

1. Department of Cell Death and Proliferation, IIBB-CSIC, IDIBAPS, Barcelona, Spain

2. Departament de Biomedicina, Facultat de Medicina, Universitat de Barcelona, Barcelona, Spain

3. Barcelona Clinic Liver Cancer Group, Liver Unit, Hospital Clínic of Barcelona, University of Barcelona, CIBEREHD, IDIBAPS, Barcelona, Spain

4. Liver Unit, Hospital Clinic, CIBEREHD, Barcelona, Spain

5. Research Center for Alcoholic Liver and Pancreatic Diseases, Keck School of Medicine of the University of Southern California, Los Angeles, CA, USA

Publisher

Impact Journals, LLC

Subject

Oncology

Cited by 53 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. APG-1252 combined with Cabozantinib inhibits hepatocellular carcinoma by suppressing MEK/ERK and CREB/Bcl-xl pathways;International Immunopharmacology;2024-09

2. BRD-810 is a highly selective MCL1 inhibitor with optimized in vivo clearance and robust efficacy in solid and hematological tumor models;Nature Cancer;2024-08-23

3. Small-molecule-based targeted therapy in liver cancer;Molecular Therapy;2024-08

4. Induction of the Inflammasome Pathway by Tyrosine Kinase Inhibitors Provides an Actionable Therapeutic Target for Hepatocellular Carcinoma;Cancers;2024-04-13

5. APG-1252 combined with Cabozantinib inhibits hepatocellular carcinoma through MEK/ERK and CREB/Bcl-xl pathways;2024-04-08